Non-natural amino acid, aminoacyl tRNA synthetase corresponding to non-natural amino acid and ROS (reactive oxygen species) response regulation system of protein formed by non-natural amino acid

By introducing non-natural amino acids and their aminoacyl tRNA synthetases to the protein, the ROS response regulation of proteins is achieved, and the accuracy and application scope of protein activity regulation in the prior art is solved, and a general Protein ROS response regulation system.

CN118994221APending Publication Date: 2024-11-22PEKING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411100108.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to achieve precise regulation of protein activity, especially the method of regulating protein activity using ROS signals has problems of random modification and limited application scope.

Method used

By introducing non-natural amino acids and their corresponding aminoacyl tRNA synthetase, gene codon expansion technology is used to introduce ROS active groups at specific locations of proteins to construct a universal and universal protein ROS response regulation system.

Benefits of technology

It has achieved site-directed quantitative introduction of ROS active groups, which is versatile and widely applicable, and can be biologically genetically encoded at any protein position, improving the accuracy and application range of protein activity regulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004989143580000031
    Figure BDA0004989143580000031
  • Figure BDA0004989143580000032
    Figure BDA0004989143580000032
  • Figure BDA0004989143580000042
    Figure BDA0004989143580000042
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to non-natural amino acid, aminoacyl tRNA synthetase corresponding to the non-natural amino acid and a protein ROS response regulation system formed by the non-natural amino acid. The non-natural amino acid with the structure shown in the formula I can respond to active oxygen, is used as a recombinant aminoacyl tRNA synthetase substrate of a gene codon extension technology, is efficiently introduced to any site of protein at a fixed point, and has universality. The non-natural amino acid is inserted into any position of any protein by utilizing gene codon extension, and an ROS'switch 'can be introduced in a biological genetic coding manner. The invention also provides an aminoacyl tRNA synthetase mutant, which can effectively improve the insertion efficiency of non-natural amino acid, is directly used for eukaryon and pronucleus, does not need additional sequence modification or modification, and is simple and convenient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a non-natural amino acid, its corresponding aminoacyl tRNA synthetase and a ROS response regulation system of the protein constructed therefrom. Background Art

[0002] Proteins are important components of living organisms, and the regulation of their activity is of universal and important significance. In recent years, a variety of protein regulation methods have been developed, such as protein dimerization activation using non-covalent interactions, non-covalent small molecule agonists or inhibitors, and small molecule probes that use the ubiquitin-proteasome system to degrade target proteins, or various strategies to regulate protein activity through conditional covalent linkage, such as fusion expression, covalent chemical modification, etc. Among these methods, chemical modification at specific positions of proteins can break the limitation of the 20 natural amino acids. Introducing chemical groups that respond to specific conditions into proteins to achieve specific conditions to regulate the activity of proteins has greatly developed molecular tools that can be used for targeted therapy, biosensors, and other functions. However, traditional chemical modifications are mainly based on natural active residues for coupling, and the number and position of the modified groups are random, which has caused great obstacles to the precise regulation of protein activity. Genetic code expansion (GCE) technology provides a solution to this problem. By introducing aminoacyl-tRNA synthetase (aaRS) and its corresponding tRNA, which are orthogonal to the organism, nonsense codons, mainly TAG, can be used to add non-natural amino acids (ncAAs) other than the 20 protein-coding amino acids to specific proteins, thereby achieving precise modification of specific protein positions. Due to its advantages in producing site-specific modified proteins, genetic codon expansion technology has been widely used in the regulation of protein activity. At present, a series of non-natural amino acid uncaging reactions that can respond to light or chemical bond breaking reactions have been developed and have been successfully applied to the artificial regulation of various protein activities. However, most studies rely on artificial external signals, but endogenous signals as indicators of physiological status are currently less concerned, and there is a huge gap.

[0003] Among the many endogenous signals in the body, reactive oxygen species (ROS) are a class of highly reactive small molecules that play an important role in physiological and pathological occurrence. Various types of ROS are mainly produced in the electron transport chain of mitochondria or oxidation reactions on the prokaryotic plasma membrane. They can also be produced in other pathways such as the respiratory burst produced by macrophage activation or oxidases such as NADPH oxidase (Nox), xanthine oxidase (XO) and uncoupled endothelial nitric oxide synthase (eNOS). ROS are widely involved in various life processes and signaling pathways in the body, and participate in maintaining the normal function of cells. Under physiological conditions, the level of ROS in the body is strictly regulated, but in some abnormal states, activated immune responses, damaged mitochondria or abnormal enhancement of some enzyme activities can lead to increased local ROS levels. For example, in tumors, due to changes in metabolic status, the levels of ROS in endogenous cancer cells and their microenvironments are higher than those in normal cells. In addition, due to the overexpression of certain oxidases, some cancer cells can be induced by small molecule drugs to further produce more ROS. In addition to tumors, ROS accumulates at high levels in lesions such as inflammation and neurodegenerative diseases, showing its excellent properties as a target for disease diagnosis and treatment. From the traditional development of small molecule drugs that can affect ROS levels for corresponding treatment, to the current use of ROS as a response regulation condition to achieve imaging or response treatment of diseases, the value of ROS targeting has gradually been recognized. Among the various strategies currently targeting ROS, the main ones are ROS-responsive small molecules for imaging or treatment and carriers or materials for drug delivery in response to microenvironmental ROS, while direct ROS regulation of proteins has hardly been explored. Previous studies have used chemical modification to block the activity of target proteins to achieve ROS response activation, but this method is greatly affected by the protein itself, and the scope of application of a single method is small, that is, it is limited by the chemical modification method itself. Therefore, using gene codon expansion technology to achieve ROS regulation of protein activity is an effective means to solve this problem.

[0004] Previous studies have reported non-natural amino acids containing ROS-responsive boronic acid groups. In 2008, a study reported a tyrosine derivative p-boronophenylalanine (BPA) containing a phenylboronic acid structure and achieved its insertion in a prokaryotic system. In 2021, a study achieved the imaging of endogenously produced ROS using BPA after extensive optimization of the expression system and GFP probe. Subsequently, in 2023, another article used this amino acid to achieve light-controlled regulation of BPA's affinity for affibody with the help of a photosensitizer. Although BPA has ROS responsiveness, its subsequent applications are very limited.

[0005] Among the many endogenous signals in the body, reactive oxygen species (ROS) are a very important class of highly reactive small molecules.

[0006] It is widely involved in various disease states, showing its excellent properties as a target for disease diagnosis and treatment.

[0007] It is necessary to develop a universal protein regulation strategy that can target ROS for activation.

[0008] However, there are still many difficulties in using ROS to regulate protein activity. Currently, there are a few studies that use chemical modification methods to give proteins a ROS "switch", but this is strictly limited by the properties of the protein itself. There is also little exploration in the existing ROS regulation of protein activity based on gene codon expansion technology. It can be said that there is no universal and easy-to-use system for regulating protein activity using ROS.

[0009] The existing technology to achieve ROS-related protein activity regulation mainly relies on introducing ROS-reactive groups into protein active sites. There are two methods for introduction. One is chemical random modification, which has the following disadvantages:

[0010] 1. The modified groups are relatively random in number and position, and can only be applied to a small number of specific proteins, making it difficult to promote their use.

[0011] The other is to introduce ROS active groups into the protein surface in a targeted and quantitative manner based on gene codon expansion technology. Previously, only p-boronophenylalanine (BPA) was genetically encoded on the protein as a ROS active group, but it lacks the properties of a universal ROS regulatory element for the following reasons:

[0012] 1. The tyrosine generated in response to ROS is similar to its own structure, and the effect of blocking protein activity by boric acid groups alone is very poor.

[0013] 2. The frequency of tyrosine backbone participating in the activity of various proteins is very low, so it is difficult to serve as a site for blocking protein activity.

[0014] 3. Compared with the prokaryotic system, its use in the eukaryotic system requires aminoacyl-tRNA synthetases from different species and specially optimized eukaryotic expression systems, which greatly limits its scope of application.

[0015] 4. Currently, its published applications in response to endogenous ROS are limited to ROS imaging, and there is no application of using endogenous ROS to regulate protein activity. Summary of the invention

[0016] In view of this, the present invention provides a non-natural amino acid, its corresponding aminoacyl tRNA synthetase and the protein ROS response control system. The non-natural amino acid provided by the present invention can introduce ROS active groups into the protein surface in a fixed and quantitative manner, and has universality and applicability. Gene codon expansion can introduce ROS "switch" at any position of any protein in the form of biological genetic coding.

[0017] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0018] A non-natural amino acid, characterized in that it has a structure shown in Formula I, or a pharmaceutically acceptable salt, solvate, prodrug or boronate form thereof;

[0019]

[0020] wherein Ra, Rb, Rc, Rd, Re, and Rf are independently selected from the group consisting of hydrogen, phenyl, halogen, C1-C7 alkyl, C1-C7 haloalkyl, C1-C7 alkoxy, C1-C7 alkoxy, C1-C7 azido, C1-C7 alkanoyl, or C1-C7 alkynyl, azido, or substituted phenyl;

[0021] The substituents in the substituted phenyl group are independently selected from: C1-C7 alkyl, C1-C7 alkoxy, C1-C7 azido, C1-C7 alkanoyl or C1-C7 alkynyl;

[0022] Rb and Rc are cyclic or not;

[0023] When Rb and Rc form a ring, Rb, Rc and the atoms to which they are connected form a 4-8 membered heterocyclic group;

[0024] The unnatural amino acid is in the L-form or the D-form.

[0025] In some embodiments, the non-natural amino acid has a structure shown in Formula II or Formula III:

[0026]

[0027]

[0028] Wherein, the structures of Ra, Rd, Re and Rf are as described in claim 1; and the non-natural amino acid is L-type or D-type.

[0029] In some specific embodiments, the non-natural amino acid has any of the following structures:

[0030]

[0031] In the present invention, the non-natural amino acid represented by formula IV is referred to as KBo.

[0032] The present invention also provides the use of the non-natural amino acid in preparing recombinant protein.

[0033] The present invention also provides a recombinant protein, wherein the amino acid at at least one position in the sequence of the wild-type protein is mutated to the non-natural amino acid described in the present invention.

[0034] In some embodiments, the unnatural amino acid is site-specifically introduced into the wild-type protein using gene codon expansion technology.

[0035] The wild-type proteins of the recombinant proteins described in the present invention include functional proteins, diagnostic proteins, functional proteins of recombinant viruses, etc. that have the effect of treating or preventing diseases, including but not limited to: recombinant antibodies, antibody-drug conjugate proteins, recombinant functional enzymes, recombinant cytokines, recombinant toxin proteins, recombinant fluorescent proteins, recombinant proteins with binding or catalytic functions, recombinant polypeptide drugs, virus-derived delivery vectors, other protein delivery vectors, etc.

[0036] The functional protein of the recombinant virus refers to the recombinant virus with KBo inserted into the protein structure, such as the AAV2 recombinant virus with KBo inserted into the capsid protein, which can be produced by eukaryotic cells.

[0037] The present invention also provides an aminoacylated tRNA synthetase mutant, wherein at least one amino acid at position 96, position 229, position 230, position 223 or position 235 of the wild-type aminoacylated tRNA synthetase is substituted.

[0038] In the present invention, the wild-type aminoacylated tRNA synthetase is derived from Methanomethylophilus alvus, the amino acid sequence of the wild-type aminoacylated tRNA synthetase is shown in SEQ ID NO: 1, and the nucleic acid sequence thereof is shown in SEQ ID NO: 2.

[0039] Furthermore, the substitution includes at least one of M96F, L229I, H233W, L229G, D230E, H233C, and V235P.

[0040] The present invention also provides a nucleic acid encoding the aminoacyl tRNA synthetase mutant.

[0041] In some specific embodiments, the nucleic acid encoding the aminoacyl tRNA synthetase mutant has:

[0042] a) the nucleotide sequence shown in SEQ ID NO: 4 or SEQ ID NO: 6; or

[0043] b) a nucleotide sequence obtained by deleting, substituting or adding one or more bases in the nucleotide sequence shown in a), and having the same or similar functions as a); or

[0044] c) A nucleotide sequence having at least 80% homology to the sequence shown in a) or b).

[0045] In some specific embodiments, the aminoacylated tRNA synthetase mutants of the present invention include mutant XE4RS and mutant 2G6RS, wherein the mutant XE4RS includes site mutations of M96F, L229I, and H233W, and its amino acid sequence is shown in SEQ ID NO: 3, and its nucleotide sequence is shown in SEQ ID NO: 4; the mutant 2G6RS includes site mutations of L229G, D230E, H233C, and V235P, and its amino acid sequence is shown in SEQ ID NO: 5, and its nucleotide sequence is shown in SEQ ID NO: 6.

[0046] The present invention also provides a protein regulation system targeting ROS activation, comprising aminoacyl tRNA synthetase or a mutant thereof, and the non-natural amino acid described in the present invention.

[0047] The present invention also provides the use of any of the following in protein regulation or preparation of ROS-responsive recombinant viruses;

[0048] 1) The non-natural amino acids described in the present invention;

[0049] 2) Recombinant proteins into which the non-natural amino acids described in the present invention are introduced;

[0050] 3) The aminoacylated tRNA synthetase mutant of the present invention;

[0051] 4) The protein regulation system of the present invention;

[0052] The protein regulation includes regulating at least one of enzyme activity, protein-protein interaction, virus infection ability, signal peptide localization ability, membrane-penetrating peptide membrane-penetrating activity, and protein fluorescence generation.

[0053] In some embodiments, the present invention provides a method for regulating viral infection ability using the non-natural amino acid of the present invention, comprising:

[0054] The lysine on the viral vector responsible for binding to the cell surface antigen is mutated into the non-natural amino acid described in the present invention, so that the virus loses the ability to infect cells;

[0055] By adding a ROS activator to the above reaction system, the virus regains its ability to infect.

[0056] In some specific embodiments, the viral vector is a recombinant AAV2 vector. Further, the lysine at position 585 on the recombinant AAV2 vector is mutated to the non-natural amino acid KBo described in the present invention.

[0057] The non-natural amino acid (such as KBo) of the present invention can release natural lysine in response to ROS, thereby restoring the virus's ability to infect. Wherein, the ROS activator includes ONOO-donor and / or hydrogen peroxide.

[0058] The present invention also provides a ROS-responsive recombinant virus, wherein the recombinant virus comprises a viral vector, wherein the lysine on the viral vector responsible for binding to a cell surface antigen is mutated into the non-natural amino acid described in the present invention.

[0059] The present invention also provides a method for site-specifically introducing non-natural amino acids into a protein, comprising:

[0060] Step 1): constructing a plasmid 1 containing a gene encoding a target protein, and a plasmid 2 carrying a gene encoding an aminoacyl tRNA synthetase or a mutant thereof and a gene encoding a corresponding tRNA, and co-transforming or co-transfecting the plasmid 1 and plasmid 2 into a host;

[0061] Step 2): adding the non-natural amino acid according to any one of claims 1 to 3 to the culture system, culturing, inducing host expression, and then separating and purifying to obtain a recombinant protein containing the non-natural amino acid.

[0062] The host includes prokaryotes and eukaryotes; the prokaryotes include Escherichia coli; the eukaryotes include yeast, various types of human and mammalian cells.

[0063] The present invention provides a non-natural amino acid of formula I structure that can respond to reactive oxygen, and as a substrate for recombinant aminoacyl tRNA synthetase of gene codon expansion technology, it can be efficiently and point-specifically introduced into any site of the protein, and has versatility and universality. The non-natural amino acid can be inserted into the protein surface using the gene codon expansion system to introduce the ROS "switch" in the form of biological genetic coding at any position of any protein. The present invention also provides aminoacyl tRNA synthetase mutants, which can realize the genetic coding of the non-natural amino acids described in the present invention on proteins, and have a high insertion efficiency, which can be directly used in eukaryotes and prokaryotes, without the need for additional sequence modification or modification, and is simple and convenient. Compared with the prior art, the present invention has the following advantages:

[0064] 1. Compared with random modification, the non-natural amino acids provided by the present invention can introduce ROS active groups into the protein surface in a fixed and quantitative manner, which is universal and applicable. Gene codon expansion can introduce ROS "switch" at any position of any protein in the form of biological genetic coding.

[0065] 2. Compared with boronic acid phenylalanine BPA, in the unnatural amino acid KBo of the present invention, the lysine blocked by the phenylboronic acid group can be effectively used for blocking various protein contact surfaces or pockets due to the steric hindrance brought by the larger volume of the phenylboronic acid group.

[0066] 3. Compared with the unnatural amino acid BPA, lysine is a positively charged amino acid under physiological conditions and is widely involved in various life activities. Therefore, its applicability is obviously wider. KBo that releases natural lysine in response to ROS has a broader range of applications.

[0067] 4. Compared with the unnatural amino acid BPA, the aminoacyl-tRNA synthetase mutant XE4RS provided by the present invention can efficiently insert KBo into the target protein and can be directly used in eukaryotes and prokaryotes without any additional sequence modification, which is very convenient.

[0068] 5. Compared with the unnatural amino acid BPA, the gene codon expansion system of the unnatural amino acid KBo and XE4RS mutant developed by the present invention has been successfully used for enzyme activity regulation, protein-protein interaction regulation and virus infection ability regulation. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] Figure 1 The aminoacylated tRNA synthetase mutant of the present invention is shown in FIG.

[0070] Figure 2 Comparison of insertion efficiency of aminoacylated tRNA synthetase 2G6RS mutant and XE4RS mutant (the experiment was to express green fluorescent protein containing the stop codon TAG at position 151. The full-length fluorescent protein can only be expressed after the unnatural amino acid is inserted, so the fluorescence value / bacterial OD value can be used as a representation of the insertion efficiency;

[0071] Figure 3 The insertion efficiency of each mutant is shown; ncAA is a non-natural amino acid, black is the insertion efficiency of the initial template sequence screened, and it is a mutant of the wild type 126G / 129A of Ma;

[0072] Figure 4 The comparison results of the catalytic luminescence signal of firefly luciferase containing KBo in the active site after treatment with and without hydrogen peroxide are shown; Figure 5 The results of recovery of enzyme luminescence activity after KBo-luciferase was treated with ROS of different concentrations and types are shown;

[0073] Figure 6 Schematic diagram of the key lysine sites of affibodyZher2 targeting HER2;

[0074] Figure 7ELISA characterization of the affinity of KBo to HER2 before and after the insertion of KBo at the key lysine site of Zher2 and treatment with hydrogen peroxide as ROS; different concentrations of wild-type Zher2, KBo-Zher2 and KBo-Zher2 treated with hydrogen peroxide);

[0075] Figure 8 Schematic diagram showing the regulation of AAV2's ability to infect cells by inserting KBo into the AAV2 recombinant virus capsid protein;

[0076] Fig. 9 The results of the experiment showing the regulation of KBo-AAV2 recombinant virus's ability to infect cells by hydrogen peroxide are shown;

[0077] Fig.10 The results of the experiment showing the regulation of the cell infection ability of KBo-AAV2 recombinant virus by hydrogen peroxide (after infection, the cells express the green fluorescent protein gene carried by the virus). DETAILED DESCRIPTION

[0078] The present invention provides non-natural amino acids and protein regulation systems targeting ROS activation. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0079] The present invention provides a non-natural amino acid of formula I, wherein the selection of each substituent is as described above.

[0080] The non-natural amino acid of the present invention is characterized in that it can respond to active oxygen, and the phenylboronic acid leaving group dissociates and releases natural lysine. It is useful as a substrate for recombinant aminoacyl tRNA synthetase in gene codon expansion technology. The aminoacyl tRNA synthetase may have other variants, including but not limited to aminoacyl tRNA synthetase XE4RS, etc.

[0081] In the present invention, the preparation method of the non-natural amino acid is not particularly limited, and any method known in the art may be used.

[0082] The present invention also provides a mutant of aminoacyl-tRNA synthetase, which has the following characteristics:

[0083] A mutant derived from the pyrrolysine aminoacylated tRNA synthetase of the species Methanomethylophilus alvus. The amino acid binding pocket of the mutant has a special residue mutation that can specifically catalyze the above-mentioned non-natural amino acid structure to produce downstream non-natural amino acid-tRNA molecules for gene codon expansion to produce the desired recombinant protein. Among them, Figure 1 The figure is a schematic diagram of the mutation site of the aminoacylated tRNA mutant of the present invention.

[0084] The present invention provides a recombinant protein, wherein the amino acid at at least one position of the sequence of the wild-type protein is mutated to the non-natural amino acid described in the present invention. The present invention also provides the use of the non-natural amino acid in preparing the recombinant protein and realizing the activation of the ROS-regulated protein.

[0085] The aminoacyl tRNA synthetase provided by the present invention can utilize the gene codon expansion technology to efficiently insert the non-natural amino acid provided by the present invention at any site of the recombinant protein. When used, the amino acid described in the present invention is introduced into a specific site of the protein, and the steric effect of the amino acid will block the physiological activity of the entire protein. When the recombinant protein is placed in a high ROS environment, the non-natural amino acid will undergo rearrangement and the blocking group will leave, releasing the natural lysine residue, thereby restoring the physiological function of the protein. Specifically, it comprises the following steps:

[0086] Step 1: co-transform / transfect the plasmid 1 containing the gene encoding the target recombinant protein and the plasmid carrying the aminoacyl tRNA synthetase / tRNA pair of the present invention into a prokaryotic / eukaryotic host organism for expressing the protein; and synthesize the non-natural amino acid of the present invention;

[0087]

[0088] (1) Synthesis of Fmoc-L-KBo-pinacol ester

[0089] Weigh 4-(hydroxymethyl)phenylboronic acid pinacol ester (2.57g, 10.9mmol) and dissolve it in 40mlTHF. Add N,N-disuccinimidyl carbonate (2.56g, 10.0mmol) at room temperature and stir at room temperature. Then drop triethylamine (1.21g, 12.0mmol) and react at room temperature for 5 hours. After that, add Fmoc-L-lysine (4.84g, 12.0mmol) to the system and react for 16h. After the reaction is completed, add water and ethyl acetate to extract three times, each time extracting 200ml. Wash three times with saturated NaCl solution, dry with anhydrous sodium sulfate, filter and spin dry, then use silica gel column chromatography to separate (DCM: MeOH = 100: 1, 0.5% acetic acid), and separate the product to dryness.

[0090] (2) Synthesis of KBo-pinacol ester

[0091] The product separated in the previous step was completely dissolved in a DCM solution containing 30% DEA, stirred at room temperature and reacted for 16 hours, the solvent was dried, and MeOH was used to dissolve it and then dripped into 500 ml of ether for recrystallization. The solid was collected by suction filtration, and the solid was washed with 30 ml of ether, and the final white solid was collected, which was the product.

[0092] (3) Generation of KBo

[0093] KBo is dissolved in LB, 2YT or other commonly used bacterial liquid culture medium, and KBo pinacol ester is rapidly hydrolyzed to obtain KBo.

[0094] Step 2: Express the target protein. During the expression process, add the non-natural amino acid of the present invention (preferably 1 mM, optionally 50 uM-2 mM) to the culture medium and express it according to the conditions required by the target recombinant protein.

[0095] Step 3: Purify the target protein or directly proceed to subsequent applications based on its properties and uses.

[0096] Step 4: Based on the needs, the recombinant protein can be activated specifically to the microenvironment or exogenous ROS.

[0097] In the present invention, the amino acid sequence of the wild-type aminoacyl tRNA synthetase is shown in SEQ ID NO: 1, and the nucleic acid sequence thereof is shown in SEQ ID NO: 2.

[0098] The sequence of SEQ ID NO: 1 is as follows:

[0099] MTVKYTDAQIQRLREYGNGTYEQKVFEDLASRDAAFSKEMSVASTD

[0100] NEKKIKGMIANPSRHGLTQLMNDIADALVAEGFIEVRTPIFISKDALARMTIT

[0101] EDKPLFKQVFWIDEKRALRPMLAPNLYSVMRDLRDHTDGPVKIFEMGSCF

[0102] RKESHSGMHLEEFTMLNLVDMGPRGDATEVLKNYISVVMKAAGLPDYDL

[0103] VQEESDVYKETIDVEINGQEVCSAAVGPHYLDAAHDVHEPWSGAGFGLER

[0104] LLTIREKYSTVKKGGASISYLNGAKIN*。

[0105] The sequence of SEQ ID NO:2 is as follows:

[0106] ATGACCGTTAAATACACCGATGCCCAGATTCAGCGTCTGCGTGAATA

[0107] TGGTAATGGTACCTATGAACAGAAAGTTTTTGAAGATCTGGCAAGTCGT

[0108] GATGCCGCATTTTCAAAAGAAATGAGCGTGGCCAGTACCGATAATGAAA

[0109] AGAAAATTAAGGGCATGATCGCCAATCCGAGTCGCCATGGCCTGACCCA

[0110] GCTGATGAATGATATTGCCGATGCACTGGTTGCCGAAGGTTTTATTGAAG

[0111] TTCGTACCCCGATTTTTATTAGCAAAGATGCACTGGCACGTATGACCATT

[0112] ACCGAAGATAAACCGCTGTTTAAACAGGTTTTCTGGATTGATGAAAAGC

[0113] GTGCCCTGCGTCCGATGCTGGCACCGAATCTGTATAGTGTTATGCGTGAT

[0114] CTGCGTGATCATACCGATGGCCCGGTGAAAATTTTTGAAATGGGCAGCT

[0115] GCTTTCGTAAAGAAAGCCATAGCGGCATGCATCTGGAAGAATTCACTAT

[0116] GCTGAATCTGGTGGATATGGGTCCGCGTGGCGATGCAACCGAAGTTCTG

[0117] AAAAATTATATTAGTGTGGTTATGAAGGCGGCAGGTCTGCCGGATTATGA

[0118] TCTGGTTCAGGAAGAAAGTGATGTTTATAAAGAAACCATCGATGTGGAA

[0119] ATTAACGGCCAGGAAGTTTGTAGTGCAGCAGTTGGCCCGCATTATCTGG

[0120] ATGCCGCCCATGATGTGCATGAACCGTGGAGTGGCGCCGGCTTTGGTCT

[0121] GGAACGCCTGCTGACCATTCGTGAAAAATATAGTACCGTGAAAAAGGGT

[0122] GGCGCCAGTATTAGTTATCTGAATGGTGCAAAAATCAACTAA.

[0123] In the present invention, the amino acid sequence of the mutant XE4RS is shown in SEQ ID NO:3, and the nucleic acid sequence thereof is shown in SEQ ID NO:4; the amino acid sequence of the mutant 2G6RS is shown in SEQ ID NO:5, and the nucleic acid sequence thereof is shown in SEQ ID NO:6.

[0124] The sequence of SEQ ID NO:3 is as follows:

[0125] MTVKYTDAQIQRLREYGNGTYEQKVFEDLASRDAAFSKEMSVASTD

[0126] NEKKIKGMIANPSRHGLTQLMNDIADALVAEEGFIEVRTPIFISKDALARFTIT

[0127] EDKPLFKQVFWIDEKRALRPMLAPNLGSVMRDLRDHTDGPVKIFEMGSCF

[0128] RKESHSGMHLEEFTMLNLVDMGPRGDATEVLKNYISVVMKAAGLPDYDL

[0129] VQEESDVYKETIDVEINGQEVCSAAVGPHYIDAAWDVHEPWSGAGFGLER

[0130] LLTIREKYSTVKKGGASISYLNGAKIN*.

[0131] The sequence of SEQ ID NO:4 is as follows:

[0132] ATGACCGTTAAATACACCGATGCCCAGATTCAGCGTCTGCGTGAATA

[0133] TGGTAATGGTACCTATGAACAGAAAGTTTTTGAAGATCTGGCAAGTCGT

[0134] GATGCCGCATTTTCAAAAGAAATGAGCGTGGCCAGTACCGATAATGAAA

[0135] AGAAAATTAAGGGCATGATCGCCAATCCGAGTCGCCATGGCCTGACCCA

[0136] GCTGATGAATGATATTGCCGATGCACTGGTTGCCGAAGGTTTTATTGAAG

[0137] TTCGTACCCCGATTTTTATTAGCAAAGATGCACTGGCACGTTTTACCATTA

[0138] CCGAAGATAAACCGCTGTTTAAACAGGTTTTCTGGATTGATGAAAAGCG

[0139] TGCCCTGCGTCCGATGCTGGCACCGAATCTGGGTAGTGTTATGCGTGATC

[0140] TGCGTGATCATACCGATGGCCCGGTGAAAATTTTTGAAATGGGCAGCTG

[0141] CTTTCGTAAAGAAAGCCATAGCGGCATGCATCTGGAAGAATTCACTATGC

[0142] TGAATCTGGTGGATATGGGTCCGCGTGGCGATGCAACCGAAGTTCTGAA

[0143] AAATTATATTAGTGTGGTTATGAAGGCGGCAGGTCTGCCGGATTATGATC

[0144] TGGTTCAGGAAGAAAGTGATGTTTATAAAGAAACCATCGATGTGGAAAT

[0145] TAACGGCCAGGAAGTTTGTAGTGCAGCAGTTGGCCCGCATTATATTGATG

[0146] CCGCCTGGGATGTGCATGAACCGTGGAGTGGCGCCGGCTTTGGTCTGGA

[0147] ACGCCTGCTGACCATTCGTGAAAAATATAGTACCGTGAAAAAGGGTGGC

[0148] GCCAGTATTAGTTATCTGAATGGTGCAAAAATCAACTAA。

[0149] The sequence of SEQ ID NO:5 is as follows:

[0150] MTVKYTDAQIQRLREYGNGTYEQKVFEDLASRDAAFSKEMSVASTD

[0151] NEKKIKGMIANPSRHGLTQLMNDIADALVAEGFIEVRTPIFISKDALARMTIT

[0152] EDKPLFKQVFWIDEKRALRPMLAPNLGSVARDLRDHTDGPVKIFEMGSCF

[0153] RKESHSGMHLEEFTMLNLVDMGPRGDATEVLKNYISVVMKAAGLPDYDL

[0154] VQEESDVYKETIDVEINGQEVCSAAVGPHYGEAACDPHEPWSGAGFGLER

[0155] LLTIREKYSTVKKGGASISYLNGAKIN*。

[0156] The sequence of SEQ ID NO:6 is as follows:

[0157] ATGACCGTTAAATACACCGATGCCCAGATTCAGCGTCTGCGTGAATA

[0158] TGGTAATGGTACCTATGAACAGAAAGTTTTTGAAGATCTGGCAAGTCGT

[0159] GATGCCGCATTTTCAAAAGAAATGAGCGTGGCCAGTACCGATAATGAAA

[0160] AGAAAATTAAGGGCATGATCGCCAATCCGAGTCGCCATGGCCTGACCCA

[0161] GCTGATGAATGATATTGCCGATGCACTGGTTGCCGAAGGTTTTATTGAAG

[0162] TTCGTACCCCGATTTTTATTAGCAAAGATGCACTGGCACGTATGACCATT

[0163] ACCGAAGATAAACCGCTGTTTAAACAGGTTTTCTGGATTGATGAAAAGC

[0164] GTGCCCTGCGTCCGATGCTGGCACCGAATCTGGGCAGTGTTGCGCGTGA

[0165] TCTGCGTGATCATACCGATGGCCCGGTGAAAATTTTTGAAATGGGCAGCT

[0166] GCTTTCGTAAAGAAAGCCATAGCGGCATGCATCTGGAAGAATTCACTAT

[0167] GCTGAATCTGGTGGATATGGGTCCGCGTGGCGATGCAACCGAAGTTCTG

[0168] AAAAATTATATTAGTGTGGTTATGAAGGCGGCAGGTCTGCCGGATTATGA

[0169] TCTGGTTCAGGAAGAAAGTGATGTTTATAAAGAAACCATCGATGTGGAA

[0170] ATTAACGGCCAGGAAGTTTGTAGTGCAGCAGTTGGCCCGCATTATGGTG

[0171] AGGCCGCCTGTGATCCGCATGAACCGTGGAGTGGCGCCGGCTTTGGTCT

[0172] GGAACGCCTGCTGACCATTCGTGAAAAATATAGTACCGTGAAAAAGGGT

[0173] GGCGCCAGTATTAGTTATCTGAATGGTGCAAAAATCAACTAA.

[0174] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0175] The means for achieving the purpose of the invention are not limited to the use of the plasmids, strains and solvents used in the embodiments of the invention. This system can also be directly used for gene codon expansion of eukaryotic systems to produce eukaryotically expressed ROS-responsive recombinant proteins. The protection scope of the present invention should include any recombinant protein produced by genetic encoding using the non-natural amino acids of the present invention and its subsequent applications. The various processes used for specific implementation are all included in the scope of the present invention. The present invention is further described below in conjunction with the embodiments:

[0176] Example 1 Insertion efficiency of the non-natural amino acids of the present invention into recombinant proteins

[0177] Superfolded green fluorescent protein (sfGFP) was selected as the protein characterizing the insertion efficiency, and the unnatural amino acid KBo was prepared into a 100 mM stock solution in DMSO. The plasmid pultra-E4RS carrying the aminoacylated tRNA synthetase mutant XE4RS (M96F, L229I, H233W) and its corresponding tRNA of the present invention and the plasmid Pet22b-sfGFP-151TAG carrying the green fluorescent protein plasmid controlled by T7 promoter and 151 site replaced with the stop codon TAG were electrotransformed into the Escherichia coli host bacteria BL21 (DE3) and coated on the plate of LB solid culture medium. On the second day, a single colony was picked and inoculated into 2ml 2xYT liquid medium for cultivation. After the bacteria reached the stationary stage, the bacterial solution was inoculated into a new 15ml 2xYT medium at a ratio of 1:50. The culture was cultured at 37°C until OD = 0.5, and the bacterial solution was evenly divided into two groups, a control group and an experimental group. Three parallel tubes were set up in each group, and each tube contained 2ml of culture medium in a shaking tube. The expression inducer IPTG was added to the control group at a final concentration of 0.1mM, and the unnatural amino acid KBo was not added. The expression inducer IPTG was added to the experimental group at a final concentration of 0.1mM and the prepared unnatural amino acid mother solution was added to the experimental group, with a final concentration of 1mM. After 16 hours, the supernatant culture was removed by centrifugation, and the cells were washed twice with PBS, and then the cells were resuspended with 2ml PBS and diluted 4 times. 200ul of each tube was added to the ELISA plate, and the fluorescence of 600nm absorption light and 485 excitation and 520 emission was read. Calculate the ratio of fluorescence / OD, and use a bar graph to compare the difference and multiple between the control group and the experimental group. The results are shown in Figure 2.

[0178] According to the above experimental method, the insertion efficiency of the non-natural amino acids of the present invention by other aminoacyl tRNA synthetase mutants described in Table 3 was investigated. The results are shown in Figure 3 .

[0179] Table 3

[0180] Mutant number 229L 230D 233H 235V 1D8 G E G G 2D9 G E L G 2G6RS G E C P 3A4 G E Y G 3E6 G E L H

[0181] Depend on Figure 2 and Figure 3 It can be seen that the aminoacylated tRNA synthetase mutants XE4RS and 2G6RS of the present invention can efficiently insert the non-natural amino acid of the present invention into the sfGFP containing a stop codon at position 151, and the insertion efficiency is significantly higher than that of other mutants in Table 3.

[0182] Example 3: Verification test that the activity of the non-natural amino acid recombinant protein of the present invention can be regulated by external ROS

[0183] A heat-stable mutant of firefly luciferase Fluc, YY5, reported in the previous literature, was selected as a protein to characterize the activity of ROS-regulated proteins, and the unnatural amino acid KBo was prepared into a 100 mM stock solution in DMSO.

[0184] The plasmid pultra-E4RS carrying the aminoacylated tRNA synthetase mutant XE4RS and its corresponding tRNA of the present invention and the luciferase YY5 plasmid Pet22b-YY5-529TAG carrying the T7 promoter controlled expression, the 529 position replaced by the stop codon TAG, and the C-terminal with a 6xHis purification tag were electrotransformed into the Escherichia coli host bacteria BL21 (DE3) and coated on the plate of LB solid culture medium. On the second day, a single colony was picked and inoculated in 2ml2xYT liquid culture medium for cultivation. After the strain was cultivated to the stationary phase, the bacterial solution was inoculated into a new 50ml2xYT culture medium at a ratio of 1:50, and cultured at 37°C until OD=0.5, and the expression inducer IPTG with a final concentration of 0.1mM and the prepared non-natural amino acid mother solution were added, and the final concentration was 1mM. After 16 hours, the supernatant culture solution was removed by centrifugation to collect the bacterial cells at the bottom of the centrifuge tube, and then the protein was purified using the Ni-NTA method. In addition, the wild-type luciferase YY5 plasmid Pet22b-YY5-WT plasmid carrying the T7 promoter to control expression was electrotransformed into the Escherichia coli host BL21 (DE3), and the wild-type protein was purified and prepared using the same method as above. After obtaining the protein solution, the non-natural amino acid recombinant protein was diluted with PBS into two groups of three copies each, each with 100ul of 4ng / ul reaction mother solution, one of which was added with 100ul, 1mM hydrogen peroxide PBS solution as the experimental group, and the other group was added with 100ulPBS as the negative group, so that the final protein concentration was 2ng / ul, and the reaction was carried out at 37℃ for 2h. The wild-type control group prepared the wild-type protein solution with the same final reaction concentration and incubated it at 37℃ with the experimental group. Then, 100ul of reaction solution was taken from each of the three groups, mixed with 100ul2x colorimetric solution, and the luminescence value was measured. The relative activity of the experimental group and the negative group relative to the wild-type control was calculated to evaluate the protein activity as an experimental characterization of the specific activation of KBo luciferase by ROS. The results are shown in Figure 4 .

[0185] The results showed that the catalytic luminescence activity of firefly luciferase containing KBo in the active site almost completely disappeared. After the addition of hydrogen peroxide, the luciferase was specifically activated by ROS and showed higher catalytic luminescence activity, proving that the inserted KBo successfully acted as a ROS "switch" to block the activity of firefly luciferase and activate it specifically in a ROS environment.

[0186] Example 4 Effects of activation of the non-natural amino acid recombinant protein of the present invention by different types of ROS

[0187] The heat-stable mutant YY5 of firefly luciferase Fluc was used as a characterization protein for ROS-regulated protein activity, and the unnatural amino acid KBo was prepared into a 100 mM stock solution in DMSO.

[0188] The plasmid pultra-E4RS carrying the aminoacylated tRNA synthetase mutant XE4RS and its corresponding tRNA of the present invention and the luciferase YY5 plasmid Pet22b-YY5-529TAG carrying the T7 promoter controlled expression, the 529 position replaced by the stop codon TAG, and the C-terminal with a 6xHis purification tag were electrotransformed into the Escherichia coli host bacteria BL21 (DE3) and coated on the LB solid medium plate. On the second day, a single colony was picked and inoculated in 2ml2xYT liquid medium for cultivation. After the bacteria were cultivated to the stationary phase, the bacterial liquid was inoculated into a new 50ml 2xYT medium at a ratio of 1:50, and cultured at 37°C until OD=0.5, and the expression inducer IPTG with a final concentration of 0.1mM and the prepared non-natural amino acid mother solution were added, and the final concentration was 1mM. After 16 hours, the supernatant culture was removed by centrifugation to collect the bacteria at the bottom of the centrifuge tube, and then the protein was purified using the Ni-NTA method. After obtaining the protein solution, the non-natural amino acid recombinant protein was diluted with PBS into twelve groups of three, each with 100ul of 4ng / ul reaction master solution. In one group, 100ul of different ROS reaction solutions were added to each portion to make the final protein concentration 2ng / ul. Each group was: PBS (Blank group), 10μM hydrogen peroxide, 100μM hydrogen peroxide, 1000μM hydrogen peroxide, 10μMONOO-donor SIN-1 compound, 100μM ONOO-donor SIN-1 compound, 10μM hydrogen peroxide and 1mM ferrous sulfate mixture (·OH group), 100μM hydrogen peroxide and 1mM ferrous sulfate mixture (OH group), 10μM sodium hypochlorite, 100μM sodium hypochlorite. React at 37℃ for 2h. Then, 100ul of reaction solution was taken from each of the three groups, mixed with 100ul2x color development solution, and the luminescence value was measured. The relative activity of the experimental group and the negative group relative to the wild-type control was calculated to evaluate the protein activity. The results are shown in Figure 5 .

[0189] The results showed that the YY5 protein with the active site replaced by KBo could be activated by different concentrations of ONOO-donor and hydrogen peroxide, while other types of ROS had poor activation effects.

[0190] Example 5: Verification test of the interaction between the non-natural amino acid recombinant protein of the present invention and the regulation of protein contact surface by external ROS

[0191] In this experiment, we selected Zher2, an affinity body that can target human Her2 antigen, and mutated the lysine at position 27 to KBo to block its affinity for Her2. We then treated it with hydrogen peroxide to restore its affinity. See the schematic diagram. Figure 6 The experimental process is as follows.

[0192] The plasmid pultra-E4RS carrying the aminoacylated tRNA synthetase mutant XE4RS and its corresponding tRNA of the present invention and the affinity Zher2 plasmid Pet22b-Zher2-27TAG carrying the T7 promoter-controlled expression, the 27 position replaced by the stop codon TAG, and the C-terminal with a 6xHis purification tag were electrotransformed into the Escherichia coli host bacteria BL21 (DE3) and coated on the LB solid medium plate. On the second day, a single colony was picked and inoculated in 2ml2xYT liquid medium for cultivation. After the strain was cultivated to the stationary phase, the bacterial liquid was inoculated into a new 50ml2xYT medium at a ratio of 1:50, and cultured at 37°C until OD=0.5, and the expression inducer IPTG with a final concentration of 0.1mM and the prepared non-natural amino acid mother solution were added, and the final concentration was 1mM. After 16 hours, the supernatant culture was removed by centrifugation to collect the bacterial cells at the bottom of the centrifuge tube, and then the protein was purified using the Ni-NTA method. After obtaining the protein solution, the next step is to verify the change in its affinity for HER2 before and after responding to hydrogen peroxide. The experiment uses ELISA as an affinity measurement experiment. The whole process is as follows:

[0193] a) Coat the ELISA 96-well plate the night before the experiment. Dilute the commercially purchased HER2 protein into the commercially purchased coating solution to a final concentration of 0.5 μg / ml. Add 100 μl to each well and place in a 4°C refrigerator for coating for 16 hours.

[0194] b) Before the experiment on the next day, take out the frozen Z HER2 -sfGFP-K27KBo protein, dilute it into PBS solution to make the final protein concentration 0.1mg / ml, and divide the protein solution into two EP tubes, each with a volume of 100μl. HER2 -sfGFP-WT, diluted to the same concentration and dispensed into an EP tube as a control.

[0195] c) Dilute the commercially available hydrogen peroxide solution to make a 1 mM PBS solution.

[0196] d) For Z HER2 -sfGFP-K27KBo protein, which was divided into a control group and a hydrogen peroxide incubation group. One of the EP tubes was added with the same volume of PBS solution at a ratio of 1:1 as the control group, and the other tube was added with the same volume of hydrogen peroxide solution prepared in the previous step at a ratio of 1:1 as the hydrogen peroxide incubation group. HER2 -sfGFP-WT protein, and add the same volume of PBS solution into it at a 1:1 ratio.

[0197] e) Incubate at 37°C for 3 hours.

[0198] f) Then, the ELISA experiment was started and 5% bovine serum albumin blocking solution was prepared.

[0199] g) Take out the ELISA plate from the refrigerator, discard the coating solution, add 300 μl of washing solution, shake and pour out. Gently tap the remaining liquid onto paper to absorb it to ensure minimal liquid residue.

[0200] h) Add 300 μl of blocking solution to each well, let stand at room temperature for one hour, and then discard the blocking solution.

[0201] i) Preparation of Z HER2 -sfGFP solution, take the incubated protein solution, dilute each protein into the blocking solution according to the corresponding concentration, add 100 μl of sample solution to each well, and incubate at room temperature with shaking for 2 hours.

[0202] j) Discard the protein solution and wash five times with washing solution at a volume of 300 μl per well, making sure that the liquid is completely discarded each time.

[0203] k) Prepare the primary antibody (mouse anti-His antibody) in blocking solution, dilute it at a ratio of 1:2000, add 100 μl to each well, and shake at room temperature for 2 hours.

[0204] l) Discard the protein solution and wash five times with washing solution at a volume of 300 μl per well, making sure that the liquid is completely discarded each time.

[0205] m) Prepare secondary antibody (rabbit anti-mouse HRP antibody) in blocking solution, dilute at a ratio of 1:2000, add 100 μl to each well, and shake at room temperature for 2 hours.

[0206] n) Discard the protein solution and wash five times with washing solution at a volume of 300 μl per well, making sure that the liquid is completely discarded each time.

[0207] o) Add 100 μl of colorimetric solution to the wells, shake at room temperature for 20 minutes, then add 100 μl of stop solution and read the absorbance at 425 nm using an ELISA reader. Figure 7 .

[0208] In this experiment, three protein concentrations were set for ELISA, namely 100 ng / ml, 30 ng / ml and 10 ng / ml.

[0209] The experimental results show that the insertion of KBo at position 27 effectively reduces Z HER2 The affinity of HER2 was significantly increased, and incubation with hydrogen peroxide could effectively restore the interaction between the two. Among the three groups, the highest multiple after incubation (DECAGE group) was more than 7 times (30ng / ml group) compared with that before incubation (CAGE group).

[0210] Example 6: Verification test of the ability of the non-natural amino acid recombinant protein of the present invention to regulate virus infection by external ROS

[0211] In this experiment, a recombinant AAV2 vector was selected, and the lysine at position 585 responsible for binding to cell surface antigens was mutated to KBo to block its binding to cells and prevent its infection process. The vector was then treated with hydrogen peroxide to restore its infection ability. Figure 8 The schematic diagram is shown in Figure 2. The experimental process is as follows.

[0212] (I) Preparation of recombinant AAV2 virus

[0213] 293FT cells were cultured in DMEM medium containing penicillin and streptomycin and 10% FBS, and cultured in a 9 cm culture dish in a 37°C 5% carbon dioxide incubator.

[0214] (1) Virus packaging

[0215] a) Before transfection, expand 293FT cells and prepare 10 90% density 9cm cell culture dishes. The volume of culture medium in each dish is 10ml.

[0216] b) The next day, when the cell density was observed to be approximately 90%, transfection was performed in a biosafety cabinet.

[0217] c) Prepare the transfection plasmid solution. Each dish should correspond to 5μg of pAAV-EGFP, 5μg of pAAV-RC2-585-TAG plasmid, 5μg of pCMV-XE4RSRS, 5μg of pHelper and 60μg of PEI transfection reagent at a concentration of 1mg / ml. In this experiment, only the eukaryotic expression plasmid pCMV-XE4RSRS carrying XE4RSRS and the AAV2 eukaryotic plasmid pAAV-RC2-585-TAG with the capsid protein 585 position mutated to TAG need to be constructed. Other plasmids and template plasmids used to construct pAAV-RC2-585-TAG can be purchased from addgene. In actual operation, calculate the amount of plasmid and PEI for all dishes, dilute them into opti-MEM according to the proportion, let them stand at room temperature for 5 minutes, then mix the plasmid and PEI solution, and let them stand at room temperature for 20 minutes. The final volume of Opti-MEM should be 10 ml.

[0218] d) Take out the culture dishes from the cell culture incubator, add 1 ml of transfection solution to each dish, shake gently to evenly distribute the plasmid, and continue to culture the culture dishes in the incubator for 6 hours.

[0219] e) Prepare a culture medium containing non-natural amino acids, add KBo to the culture medium at a final concentration of 1 mM, remove the small dish 6 hours after transfection, remove the culture medium containing the transfection solution, add culture medium containing the corresponding concentration of non-natural amino acids, and then continue to culture in the incubator for 72 hours.

[0220] (2) Virus purification

[0221] a) After 72 hours of medium replacement, take out the culture dishes, remove the supernatant medium, add 2 ml of PBS to each dish, blow the cells directly off, and collect the cell suspension.

[0222] b) Centrifuge the cell suspension at 1000 rpm for 5 minutes and collect the cell pellet.

[0223] c) Resuspend the cells in PBS at a volume of 1 ml per dish, add 1 / 10 volume of chloroform, and shake at 37° C. for 1 hour.

[0224] d) After 1 hour, the cell solution was removed and sodium chloride was added to a final concentration of 1 M to further precipitate the protein. The cell solution was centrifuged at 12,000 rpm for 20 minutes. The supernatant water layer was carefully aspirated and the chloroform layer was discarded.

[0225] e) PEG8000 at a final concentration of 10% was added to the supernatant, and the mixture was incubated on ice with shaking for 1 hour to precipitate the virus.

[0226] f) The cell suspension was centrifuged at 12000 rpm for 20 minutes, the aqueous layer was removed by aspiration, and the virus was re-dissolved in 500 μl PBS.

[0227] g) Add 1 μl of Benzonase to the virus solution, mix well, and incubate at 37°C for 30 minutes.

[0228] h) After 30 minutes, add chloroform to the virus solution at a ratio of 1:1 and mix thoroughly to precipitate.

[0229] i) Centrifuge the virus solution at 12,000 rpm for 20 minutes, carefully aspirate the supernatant water layer, and discard the chloroform layer.

[0230] J) qPCR was used to measure the virus titer. The obtained virus was filtered and then packaged and frozen.

[0231] In addition, the packaging and purification steps of AAV2-585K are the same as above. When transfecting, add 5 μg of pAAV-EGFP, 5 μg of pAAV-RC2-585-TAG plasmid, 5 μg of pHelper and 45 μg of 1 mg / ml PEI transfection reagent. There is no need to add KBo when changing the solution. The other steps are the same.

[0232] (II) Infection of cells by recombinant AAV2 virus before and after responding to hydrogen peroxide

[0233] Next, the infection experiment of the recombinant AAV2 virus was carried out.

[0234] (1) Cell culture and plating

[0235] 293T cells were cultured in DMEM medium containing penicillin and streptomycin and 10% FBS. 9 cm culture dishes were used for culture in a 37°C 5% CO2 incubator. 293T cells were passaged one day before infection, with 4 × 10 cells per well. 4 Plate 48-well plates.

[0236] (2) Virus infection experiment

[0237] a) On the second day after plating, take an appropriate amount of frozen virus and divide it into two PCR tubes, prepare 1mM hydrogen peroxide solution. One PCR tube is used as the control group, and an equal volume of PBS is added to it. The other PCR tube is used as the experimental group, and an equal volume of hydrogen peroxide solution is added to it for treatment. AAV2-585K is taken as the wild-type control group. The three PCR tubes are incubated at 37°C for 3 hours.

[0238] b) Three hours later, the incubated virus was taken out and the corresponding virus was added to the wells of a 48-well plate at a concentration of MOI = 3000 for infection for 24 hours.

[0239] c) After 24 hours, take out the 48-well plate and take pictures. Place the cells under an inverted microscope for observation. Use the green fluorescence channel to take pictures. Choose an appropriate exposure time and ensure that all pictures are taken under the same conditions. Fig.10 .

[0240] d) Then, the supernatant of all wells was removed by aspiration, 50 μl of trypsin was added to the wells, and the cells were incubated at room temperature for 1 minute for digestion. Then, 300 μl of culture medium was added to the wells for neutralization, and the cells were resuspended with a pipette and transferred to an EP tube.

[0241] e) The cell suspension was centrifuged at 1000 rpm for 8 minutes, the supernatant was discarded, and the cells were washed twice with PBS and analyzed by flow cytometry. Fig. 9 .

[0242] The results showed that the insertion of KBo at position 585 effectively blocked the virus's infectivity to cells, while incubation with hydrogen peroxide effectively restored the infectivity of the recombinant virus, and compared with the wild type with lysine at position 585. After incubation with hydrogen peroxide, the recombinant AAV2 can reach more than 70% of its activity, proving that this strategy can be effectively applied to the development of ROS-responsive recombinant viruses.

[0243] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An unnatural amino acid, characterized in that It has the structure shown in Formula I, or a pharmaceutically acceptable salt, solvate, prodrug or boric acid ester thereof; wherein Ra, Rb, Rc, Rd, Re, and Rf are independently selected from the group consisting of hydrogen, phenyl, halogen, C1-C7 alkyl, C1-C7 haloalkyl, C1-C7 alkoxy, C1-C7 azido, C1-C7 alkanoyl, or C1-C7 alkynyl, azido, or substituted phenyl; The substituents in the substituted phenyl group are independently selected from: C1-C7 alkyl, C1-C7 alkoxy, C1-C7 azido, C1-C7 alkanoyl or C1-C7 alkynyl; Rb and Rc are cyclic or not; When Rb and Rc form a ring, Rb, Rc and the atoms to which they are connected form a 4-8 membered heterocyclic group; The unnatural amino acid is in the L-form or the D-form.

2. The unnatural amino acid according to claim 1, characterized in that The non-natural amino acid has a structure shown in Formula II or Formula III: Wherein, the structures of Ra, Rd, Re and Rf are as described in claim 1; wherein, the non-natural amino acid may be L-type or D-type.

3. The non-natural amino acid according to claim 1 or 2, characterized in that It has any of the following structures:

4. Use of the non-natural amino acid according to any one of claims 1 to 3 in the preparation of recombinant proteins.

5. A recombinant protein, characterized in that The amino acid at at least one position in the sequence of the wild-type protein is mutated to the non-natural amino acid according to any one of claims 1 to 3.

6. The recombinant protein according to claim 5, characterized in that The non-natural amino acid is site-specifically introduced into the wild-type protein using gene codon expansion technology.

7. The recombinant protein according to claim 5 or 6, characterized in that The wild-type proteins include recombinant antibodies, antibody-drug conjugate proteins, recombinant functional enzymes, recombinant cytokines, recombinant toxin proteins, recombinant fluorescent proteins, recombinant proteins with binding or catalytic functions, recombinant polypeptide drugs or virus-derived delivery vectors that have the effect of treating or preventing diseases.

8. An aminoacylated tRNA synthetase mutant, characterized in that The wild-type aminoacyl tRNA synthetase is obtained by causing at least one mutation among M96F, L229I, H233W, L229G, D230E, H233C and V235P.

9. The aminoacylated tRNA synthetase mutant according to claim 8, characterized in that The wild-type aminoacylated tRNA synthetase is derived from Methanomethylophilus alvus, and the amino acid sequence of the wild-type aminoacylated tRNA synthetase is shown in SEQ ID NO:

1.

10. A nucleic acid encoding the aminoacyl-tRNA synthetase mutant according to claim 8 or 9.

11. A protein regulatory system targeting ROS activation, characterized in that: The invention comprises an aminoacyl tRNA synthetase or a mutant thereof, and the non-natural amino acid according to any one of claims 1 to 3.

12. The protein regulation system according to claim 11, characterized in that: The aminoacylated tRNA synthetase mutant is the aminoacylated tRNA synthetase mutant according to claim 8 or 9.

13. Use of any of the following in protein regulation or preparation of ROS-responsive recombinant viruses; 1) The unnatural amino acid according to any one of claims 1 to 3; 2) The recombinant protein according to any one of claims 5 to 7; 3) The aminoacyl tRNA synthetase mutant according to claim 8 or 9; 4) The nucleic acid of claim 10; 5) The protein regulation system according to claim 11 or 12; The protein regulation includes regulating at least one of enzyme activity, protein-protein interaction, virus infection ability, signal peptide localization ability, membrane-penetrating peptide membrane-penetrating activity, and protein fluorescence generation.

14. A method for site-specifically introducing non-natural amino acids into a protein, characterized in that: include: Step 1): constructing a plasmid 1 containing a gene encoding a target protein, and a plasmid 2 carrying a gene encoding an aminoacyl tRNA synthetase or a mutant thereof and a gene encoding a corresponding tRNA, and co-transforming or co-transfecting the plasmid 1 and plasmid 2 into a host; Step 2): adding the non-natural amino acid according to any one of claims 1 to 3 to the culture system, culturing, inducing host expression, and then separating and purifying to obtain a recombinant protein containing the non-natural amino acid.

15. The method according to claim 14, characterized in that The host includes prokaryotes and eukaryotes; The prokaryotes include Escherichia coli; Such eukaryotic organisms include yeast, human and mammalian cells.